Track Mankind Pharma Limited live share price with 52 week high and low, chart views, fundamentals, financial statements, ratios, peer comparison, dividends, bonuses/splits and company details.
Switch between 1 Day, 5 Day, 1 Month and 1 Year chart views.
Mankind Pharma Limited is an Indian pharmaceutical and consumer-health company with a strong domestic presence. It develops, manufactures and markets branded prescription medicines, over-the-counter healthcare products and specialty therapies through a wide distribution and medical-representative network.
The company serves acute, chronic and specialty therapy areas including anti-infectives, gastrointestinal, respiratory, cardiovascular, anti-diabetes, dermatology, pain management, vitamins, gynaecology and fertility. Its consumer-health portfolio includes brands used in sexual wellness, pregnancy testing, antacids, nutrition and skincare.
The acquisition of Bharat Serums and Vaccines expanded the group into women’s health, fertility, critical care and selected biologic products. Investors commonly monitor domestic market-share gains, chronic-therapy growth, consumer-health performance, acquisition integration, margins, net debt and research productivity.
Mankind Pharma is generally analysed through domestic pharmaceutical formulations, consumer healthcare, international operations and specialty products. The company’s results can be influenced by prescription growth, product launches, price regulation, distribution reach, regulatory compliance and acquisition-related financing.
Product portfolios, rankings, market shares and acquisition disclosures can change. Verify the latest information from Mankind Pharma investor presentations, annual reports and exchange filings.
Mankind Pharma earns revenue by developing, manufacturing, licensing and marketing prescription medicines and consumer-health products. Its domestic branded-generics model relies on physician engagement, brand building, manufacturing quality, field-force productivity and broad distribution across metros, smaller cities and rural markets.
The domestic pharmaceutical business includes acute and chronic therapies. The consumer-health portfolio sells selected non-prescription brands through pharmacies, distributors, modern trade and digital channels. The international and specialty businesses add products in selected overseas markets and higher-entry-barrier therapies.
Key profit drivers include volume growth, new-product launches, chronic-therapy mix, gross margin, advertising and employee costs, research spending and operating leverage. Important risks include regulatory action, product-quality issues, price controls, competition, raw-material disruption and unsuccessful acquisition integration.
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Revenue from Operations | ₹8,749 Cr | ₹10,260 Cr | ₹12,207 Cr |
| Adjusted EBITDA | ₹1,913 Cr | ₹2,529 Cr | ₹3,159 Cr |
| Adjusted EBITDA Margin | 21.9% | 24.6% | 25.9% |
| Profit After Tax | ₹1,310 Cr | ₹1,941 Cr | ₹2,007 Cr |
| Earnings Per Share | ₹32.72 | ₹48.45 | ₹46.30 |
| Domestic Revenue Mix | Majority of revenue | Majority of revenue | Majority of revenue |
Figures are educational snapshots and may be revised. Verify the latest audited or quarterly data from Mankind Pharma, NSE and BSE filings.
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Equity Share Capital | ₹40 Cr | ₹40 Cr | ₹41 Cr |
| Reserves and Surplus | ₹7,030 Cr | ₹8,818 Cr | ₹14,900 Cr |
| Borrowings | ₹218 Cr | ₹173 Cr | ₹10,500 Cr |
| Property, Plant and Equipment | ₹2,400 Cr | ₹2,750 Cr | ₹5,900 Cr |
| Goodwill and Intangibles | ₹1,250 Cr | ₹1,400 Cr | ₹15,000 Cr |
| Cash and Investments | ₹3,260 Cr net cash position | ₹3,260 Cr net cash position | Lower after BSV acquisition funding |
| Balance-sheet Focus | Net cash and growth investment | Strong liquidity | Acquisition debt and deleveraging |
Figures are educational snapshots and may be revised. Verify the latest audited or quarterly data from Mankind Pharma, NSE and BSE filings.
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Operating Cash Flow | Positive | Strong | Positive despite acquisition year |
| Capital Expenditure | Manufacturing and R&D investment | Capacity and product investment | Manufacturing, integration and specialty investment |
| Acquisition Cash Flow | Not material | Not material | Large outflow for Bharat Serums and Vaccines |
| Financing Cash Flow | Low leverage profile | Low leverage profile | Debt and equity funding linked to acquisition |
| Investor Monitorable | Cash conversion | Free cash flow | Deleveraging and integration cash generation |
Figures are educational snapshots and may be revised. Verify the latest audited or quarterly data from Mankind Pharma, NSE and BSE filings.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Adjusted EBITDA Margin | 21.9% | 24.6% | 25.9% |
| Net Profit Margin | 15.0% | 18.9% | 16.4% |
| Return on Capital Employed | Healthy | Improved | Temporarily affected by acquisition capital |
| Chronic Portfolio Share | Growing | Growing | About 37% of domestic pharma portfolio |
| Balance-sheet Position | Net cash | Net cash | Net debt after BSV acquisition |
Figures are educational snapshots and may be revised. Verify the latest audited or quarterly data from Mankind Pharma, NSE and BSE filings.
| Company | NSE Symbol | Business Focus | Investor Comparison Point |
|---|---|---|---|
| Mankind Pharma Limited | MANKIND | Domestic branded medicines, consumer health and specialty pharma | Domestic growth, BSV integration, margins and deleveraging |
| Sun Pharmaceutical Industries Limited | SUNPHARMA | Specialty and generics with global operations | Specialty pipeline, geographic mix and margins |
| Cipla Limited | CIPLA | India, respiratory and global generics | Domestic franchise, US business and product pipeline |
| Dr. Reddy’s Laboratories Limited | DRREDDY | Global generics and pharmaceutical services | US exposure, launches, margins and R&D |
| Torrent Pharmaceuticals Limited | TORNTPHARM | India-focused branded formulations and selected international markets | Chronic portfolio, domestic growth and acquisition strategy |
Figures are educational snapshots and may be revised. Verify the latest audited or quarterly data from Mankind Pharma, NSE and BSE filings.
| Year | Dividend Detail | Note |
|---|---|---|
| Latest Financial Year | Dividend details must be verified from official filings | Check board recommendation, record date, ex-date and shareholder approval |
| Historical Dividends | The company has declared dividends after listing | Amounts and dates can change; use NSE/BSE corporate-action records |
| Dividend Policy | Depends on profit, cash flow, debt and investment needs | Past dividends do not guarantee future payments |
| Action | Detail | Note |
|---|---|---|
| Bonus Issue | No current bonus detail is asserted on this page | Verify the latest exchange announcements |
| Face Value | ₹1.00 per equity share | Verify against the latest capital structure filing |
| Stock Split | No current split detail is asserted on this page | Check official corporate-action history before relying on adjusted prices |
Corporate actions can change after publication. Verify dividend, bonus, split, record-date and entitlement details from official company and exchange filings.
These FAQs explain Mankind Pharma medicines, consumer-health products, business model, financial risks, dividends and the operating indicators retail investors commonly monitor.
Mankind Pharma is an Indian pharmaceutical and consumer-health company. It develops, manufactures and markets prescription medicines, over-the-counter products and healthcare brands across acute, chronic and specialty therapies.
The company reports a domestic pharmaceutical business, consumer healthcare business and international business. Its portfolio also includes specialty products through Bharat Serums and Vaccines, particularly in women’s health, fertility and critical-care therapies.
Its portfolio spans anti-infectives, gastrointestinal, respiratory, cardiovascular, anti-diabetes, dermatology, pain management, vitamins and minerals, neurology, gynaecology, fertility and other specialty areas. Product availability changes over time.
Well-known consumer brands associated with the group include Manforce, Prega News, Gas-O-Fast, HealthOK and AcneStar. Customers should use medicines and healthcare products according to approved instructions and professional medical advice where applicable.
Revenue comes mainly from the sale of prescription medicines, consumer healthcare products and specialty pharmaceutical products in India and selected international markets. Growth depends on prescription demand, brand performance, distribution reach, product launches, pricing and acquisitions.
The acquisition expanded Mankind Pharma into higher-entry-barrier specialty areas such as women’s health, fertility, critical care and certain biologic products. Investors should monitor integration, debt reduction, margins and cross-selling benefits.
Important factors include revenue growth, domestic market share, new launches, chronic-therapy growth, regulatory observations, raw-material costs, pricing controls, acquisition integration, debt, margins, competition and quarterly earnings.
Risks include regulatory non-compliance, product recalls, price controls, intense competition, dependence on key brands, raw-material supply disruption, litigation, acquisition integration, higher debt and slower prescription or consumer demand.
The company may declare dividends subject to profitability, capital requirements and board and shareholder approvals. Investors should verify the latest dividend amount, record date, ex-date and payment details from NSE, BSE and company filings.
Corporate-action history should be checked through official exchange records. Do not infer a bonus or split from historical price charts alone because adjusted prices may reflect other market events.
Monitor domestic pharmaceutical growth, chronic share, consumer-health growth, BSV performance, international revenue, gross margin, EBITDA margin, research spending, working capital, net debt, free cash flow and management guidance.
Common comparisons include Sun Pharmaceutical Industries, Cipla, Dr. Reddy’s Laboratories, Torrent Pharmaceuticals and Lupin. Comparisons should consider therapy mix, domestic exposure, exports, margins, research pipeline, debt and valuation.
Beginners can study the company by first understanding its domestic branded-generics model, consumer-health portfolio, specialty expansion, distribution network, margins and acquisition-related debt rather than relying only on the current share price.
Use Mankind Pharma investor relations, NSE and BSE filings for audited financial statements, quarterly results, shareholding patterns, corporate actions and material announcements. Third-party information should be cross-checked with official disclosures.
